Amino.Desk

SS-31 (elamipretide, Forzinity)

Updated Nov 17, 2026 · Clinical review: pending

SS-31 is the research name for elamipretide. In September 2025 the FDA gave it accelerated approval as Forzinity, the first treatment for Barth syndrome, a rare inherited mitochondrial disease that affects about 150 people in the US. Online it is sold for energy and longevity, uses that have not been tested.

What it is

Elamipretide binds to cardiolipin, a fat in the inner membrane of mitochondria, the parts of the cell that produce energy. In Barth syndrome, cardiolipin is abnormal.

What the evidence shows

The trial behind the approval enrolled 12 patients. It missed both of its main goals: elamipretide did not beat placebo on walking distance or on fatigue scores. The FDA granted accelerated approval based on an improvement in knee-muscle strength, which it judged reasonably likely to predict real benefit, and required a new placebo-controlled trial to confirm it.

That is why the grade is B, even though the drug is approved. There is no published evidence that it improves energy, endurance or aging in healthy people.

Dosing on the label

For patients with Barth syndrome weighing at least 30 kg, the label dose is 40 mg injected under the skin once a day. The dose is reduced in severe kidney impairment, because the drug leaves the body through the kidneys.

No dose is established for any other use.

Side effects

Common questions

What is SS-31 approved for?

As Forzinity (elamipretide), it received FDA accelerated approval in September 2025 for Barth syndrome only.

Does SS-31 improve energy or slow aging?

There is no published evidence that it improves energy, endurance or aging in healthy people.

What is the label dose?

For patients with Barth syndrome weighing at least 30 kg, 40 mg injected under the skin once a day. No dose is established for any other use.

Added in the latest update. These answers summarize the sections above; sources are listed below.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy